596817-02-6Relevant articles and documents
PYRROLIDINE AND PIPERIDINE COMPOUNDS
-
Paragraph 0250-0251; 0254-0255, (2021/05/15)
The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors
Sattigeri, Jitendra A.,Andappan, Murugaiah M.S.,Kishore, Kaushal,Thangathirupathy, Srinivasan,Sundaram, Sinduja,Singh, Shuchita,Sharma, Suchitra,Davis, Joseph A.,Chugh, Anita,Bansal, Vinay S.
scheme or table, p. 4087 - 4091 (2009/04/10)
The induction of conformationally restricted N-(aryl or heteroaryl)-3-azabicyclo[3.1.0]hexane derivatives at P2 region of compounds of 2-cyanopyrrolidine class was explored to develop novel DPP-IV inhibitors. The synthesis, structure-activity r
NEW COMPOUNDS
-
Page/Page column 21, (2008/06/13)
The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.
2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS DPP-IV INHIBITORS
-
Page 50-51, (2010/02/09)
A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X is CFH, or CF?2#191, R?1? is the moiety represented by the formula: [wherein R?2? is (lower) alkyl, R?3? is phenyl-(lower)alkyl, and the like.], and the like.] Compounds of formula (I) inhibit DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.
NEW COMPOUNDS
-
Page/Page column 17, (2008/06/13)
The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.